Skip to main content
See every side of every news story
Published loading...Updated

Anvisa Approves New Indications for Medication that Treats Breast Cancer

The National Agency for Health Surveillance (Anvisa) approved new therapeutic indications for the drug Trodelvy (sacituzumab govitecana), used in the treatment of adult patients with triple-negative breast cancer (MCTN).
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

8 Articles

Use of Trodelvy is to treat triple-negative breast cancer, more aggressive and with fewer therapeutic options The post Anvisa approves new treatments with medication for breast cancer apareceu primeiro em AMAZONAS CURUAL.

Trodelvy begins to have two new indications for patients with advanced disease, including use in combination with pembrolizumab

·Brasília, Brazil
Read Full Article
Tribuna OnlineTribuna Online
+5 Reposted by 5 other sources

The National Health Surveillance Agency (Anvisa) approved new therapeutic indications for Trodelvy (sacituzumab govitecana), used in the treatment of adult patients with triple-negative breast cancer (MCTN).

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Tribuna Online broke the news on Thursday, September 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal